CRSP vs NTLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRSP Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Options & Structure while NTLA counters with relative strength in Momentum & Technical. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus NTLA at N/M Forward P/E and -826.0% operating margin (-48.0% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | NTLA Revenue | CRSP Op. Margin | NTLA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -5087.8% | -298.6% | NTLA |
| FY2019 | $290M | $40M | 16.1% | -246.8% | CRSP |
| FY2020 | $0M | $60M | -49295.5% | -235.5% | NTLA |
| FY2021 | $910M | $30M | 40.8% | -810.4% | CRSP |
| FY2022 | $0M | $50M | -56190.4% | -879.0% | NTLA |
| FY2023 | $370M | $40M | -60.0% | -1420.5% | CRSP |
| FY2024 | $40M | $60M | -1250.4% | -923.1% | NTLA |
| FY2025 | $0M | $70M | -18933.6% | -651.7% | NTLA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | NTLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $1.5B | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +1325.1% | -48.0% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -2058.6% | -826.0% | Higher Margin | NTLA |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -25.6% | -62.6% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 20% ($8โ$18) | Stronger Trend | NTLA |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | 2.30ฮฒ ยท 87% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 49.9 / 100 (HOLD) | Higher Composite | NTLA |